Alembic rides generic Abilify wave amid compliance wins
This article was originally published in Scrip
Executive Summary
Shares of Alembic Pharmaceuticals surged on Indian bourses, after the US FDA cleared the first set of generic versions of Otsuka's schizophrenia and bipolar disorder drug Abilify (aripiprazole).
You may also be interested in...
Torrent On Course For Buy, US Momentum
Torrent Pharmaceuticals Ltd may have opted out of the race for the injectables firm Gland Pharma Ltd, but the Indian company stays interested in a buy to build its "hospital presence".
Alembic Setting Up For US Oncology Play
Alembic Pharmaceuticals, which has seen a dazzling FY16, appears set to build on its strong showing in the US with plans for filings in the oncology and dermatology space and a potential ramp up of its own label products there.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.